ClinicalTrials.gg
RecruitingNCT07412249RICSICASUpdated Apr 3, 2026

Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis

An interventional study of Remote ischemic conditioning in Carotid Stenosis, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by General Hospital of Shenyang Military Region · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Carotid Stenosis with a site in China — 33 open to participants now, 37 under way, 1 of them phase 3. Carotid Stenosis · China.

Planned enrollment
10th of 37
300 · median 178
Started
2026
with 7 others
No phase
26 of 71
13 open now
Primary completion
2027-11
later than 24 of 36 live
Registered
65th of 71
by date
Lead sponsor
2 of 71
General Hospital of Shenyang Military Region

Among the 71 studies in Carotid Stenosis with a site in China, this one is the 10th largest by planned enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2026, is one of 26 with no phase, reaches primary completion later than 24 of the 36 other live ones, and was the 65th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

33 of the 71 studies in Carotid Stenosis with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carotid Stenosis with a site in China, or all of them as a file.
02

Study summary

Remote ischemic conditioning (RIC) has emerged as a promising non-invasive strategy to protect the brain, with evidence suggesting its benefit in patients with carotid artery stenting (CAS). However, the long-term benefit and safety of chronic RIC in this population remain unknown. This trial aims to evaluate whether chronic RIC reduces the incidence of major vascular events and improves clinical outcomes in high-risk patients with carotid artery stenosis who received CAS.

03

Conditions studied

  • Carotid Stenosis

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 40 years old;
  • Patients with symptomatic moderate to severe stenosis of the internal carotid artery;
  • History of ipsilateral cerebral ischemic symptoms within the past 180 days;
  • Planned for carotid artery stent;
  • Essen Score ≥ 3;
  • Modified Rankin Scale score of 0 or 1;
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled severe hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg despite medication)
  • Subclavian artery stenosis ≥ 50% or presence of subclavian steal syndrome
  • Severe hematological disorders or significant coagulation abnormalities
  • to remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limbs, or peripheral vascular disease in the distal upper limbs
  • Severe comorbid conditions with a of less than 1 year
  • Participation in another clinical trial within the past 3 months or ongoing participation
  • Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    RIC group

    The RIC protocol involves bilateral upper-arm cuff inflation to 200 mmHg (5-min inflation/5-min deflation, 5 cycles) performed 1-2 times daily, starting 3 days before CAS and continuing for 12 months post-procedure.

    Device: Remote ischemic conditioning

  • No intervention
    Control group

    no RIC treatment

Interventions

  • DeviceRemote ischemic conditioning

    The RIC protocol involves bilateral upper-arm cuff inflation to 200 mmHg (5-min inflation/5-min deflation, 5 cycles) performed 1-2 times daily, starting 3 days before CAS and continuing for 12 months post-procedure.

06

What researchers measure

Primary outcomes

  1. time to the first occurrence of any component of the composite endpoint within 12 months post-randomization

    the composite endpoint includes ischemic stroke, hemorrhagic stroke, myocardial infarction \[including coronary revascularization\], TIA, or vascular death

    Time frame: 1 year

Secondary outcomes

  1. composite of periprocedural death, stroke, or myocardial infarction

    Time frame: 30±3 days

  2. occurence of non-fatal stroke and TIA

    Time frame: 1 year

  3. occurence of nonfatal myocardial infarction

    Time frame: 1 year

  4. numbers of new silent cerebral infarcts on Magnetic Resonance Imaging

    Time frame: 1 year

  5. occurence of ipsilateral (to the stented artery) nonfatal stroke and transient ischemic attack

    Time frame: 1 year

  6. degree of in-stent restenosis (≥50%) on Computed Tomography Angiography

    Time frame: 1 year

  7. change in collateral circulation status (assessed by Computed Tomography Angiography or Digital Subtraction Angiograph) from baseline to 12 months

    Time frame: 1 year

  8. all-cause mortality

    Time frame: 1 year

  9. changes in modified Rankin Scale (mRS) scores over time

    The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome

    Time frame: 1 year

  10. occurrence of contrast staining on brain computerized tomography

    Time frame: 1 hours and 24 hours after carotid artery stenting

  11. occurrence of cerebral hyperperfusion syndrome

    Time frame: 24 hours after carotid artery stenting

  12. occurence of new infarct on brain magnetic resonance imaging

    Time frame: 24 hours after carotid artery stenting

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2027, 20 months after the start.

Of 51 non-industry interventional studies with no phase under Carotid Stenosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's planned 20 months is below that.

Counting every sponsor, half of 62 studies reached it within 27 months; a quarter within 19 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartActual
Mar 4, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07412249
Lead sponsor
General Hospital of Shenyang Military Region
Responsible party
Hui-Sheng Chen (Director, General Hospital of Shenyang Military Region) — Principal investigator
First posted
Feb 17, 2026
Start date
Mar 4, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Apr 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion